![FDA approves niraparib for treatment of recurrent ovarian cancer](https://www.hoaapharmacy.com/wp-content/uploads/2017/10/Screen-Shot-2017-10-03-at-9.56.18-AM.png)
Ovarian cancer is one of the more lethal cancers that women can develop. It is often associated with either inherent mutations in a woman’s own DNA, or mutations that develop within an ovarian cancer, that impairs the ability of your body to repair DNA breaks. PARP (poly ADP-ribose polymerase) inhibitors are oral medications that further… Read more »